The FDA has asked the manufactures of Opana ER to remove the opioid from the U.S. market due to the public health risk of abuse…
New Kits Address Pediatric-to-Adult-Care Transition
The transition from pediatric to adult care can be a rocky one. For many rheumatology patients, any problems in the move can cause gaps in care. To address this issue, the American College of Rheumatology (ACR) joined the American College of Physicians’ (ACP) Pediatric to Adult Care Transitions Initiative. The Initiative is a project spearheaded…
MicroRNA Mediates Gene Regulation That Underlies JIA Pathology
Through the use of large-scale transcriptome analysis, researchers have gained insight into the role of innate immunity in juvenile idiopathic arthritis (JIA) pathology. Specifically, transcriptomes of neutrophils in chronic inflammatory states demonstrate extensive network rewiring caused by microRNA, suggesting a role for alternative splicing in JIA pathogenesis…
Large Group Study of Systemic JIA Patients Provides Insight into Disease Pathology
In a large group genetic analysis, researchers identified an association between the class II HLA region, including HLA-DRB1*11, and systemic juvenile idiopathic arthritis (sJIA), implicating adaptive immune molecules in sJIA’s pathogenesis and reinforcing its unique genetic position among JIA subtypes…
Disease Duration, Corticosteroid Use Predict Etanercept Response in JIA
NEW YORK (Reuters Health)—Almost half of juvenile idiopathic arthritis (JIA) patients treated with etanercept achieve minimal disease activity after one year of treatment, according to new findings. Younger patients and those who did not require corticosteroid treatment were more likely to have an excellent response, Dr. Kimme Hyrich of the University of Manchester in the…
Keep Kids on the Move
How to encourage physical activity and exercise in juvenile idiopathic arthritis
Pursue Remission
Disease remission should be the goal for all rheumatologists treating childhood arthritis